Clinical Research Directory
Browse clinical research sites, groups, and studies.
Expanded Access Program for CT1812 (Zervimesine)
Sponsor: Cognition Therapeutics
Summary
This is a multi-center, open label, expanded access program (EAP) that will provide 100 mg CT1812 for up to one year to participants with mild-to-moderate DLB.
Official title: A Single-arm, Open-label, Expanded Access Program to Provide 100 mg CT1812 (Zervimesine) and to Collect Long-term Safety and Efficacy Data in Participants With Mild-to-moderate Dementia With Lewy Bodies (DLB).
Key Details
Gender
All
Age Range
50 Years - 86 Years
Study Type
EXPANDED_ACCESS
Enrollment
Not specified
Start Date
Not specified
Completion Date
Not specified
Last Updated
2026-05-28
Healthy Volunteers
Not specified
Conditions
Interventions
zervimesine
Zervimesine (CT1812) was shown to be safe and well tolerated in a study of healthy volunteers and in Phases 1 and 2 studies of participants with mild to moderate AD and DLB. This is an open label expanded access program designed to provide access to CT1812 and to evaluate the long-term safety of CT1812 administered once daily in adults aged 50 to 86 who have been diagnosed with mild to moderate DLB (the targeted clinical indication for CT1812). Participants will receive 100 mg of CT1812 once daily for the entire study.
Locations (8)
Banner Sun Health Research Institute
Sun City, Arizona, United States
Stanford Neuroscience Heath Center
Palo Alto, California, United States
University of Colorado Denver - Anschutz Medical Campus
Aurora, Colorado, United States
University of Miami - Department of Neurology
Boca Raton, Florida, United States
Mayo Clinic - Rochester
Rochester, Minnesota, United States
Columbia University Medical Center
New York, New York, United States
Ohio State University Wexner Medical Center (OSUWMC)
Columbus, Ohio, United States
Summit Headlands LLC
Portland, Oregon, United States